Evaluate the Pharmacokinetics of Oral Arsenic Trioxide Solution Under Fasting and Fed Conditions, to Compare Intravenous Arsenic Trioxide, in Acute Promyelocytic Leukemia
Phase 1 Completed
12 enrolled
TUD-APOLLO-064
Phase 3 Completed
135 enrolled
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
Phase 2 Completed
78 enrolled 8 charts
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Phase 3 Completed
106 enrolled 14 charts
APL0406
Phase 3 Completed
276 enrolled
Combined Tretinoin and Arsenic Trioxide for Patients With Newly Diagnosed Acute Promyelocytic Leukemia Followed by Risk-Adapted Postremission Therapy
Phase 2 Completed
17 enrolled 8 charts
Leukemia SPORE Phase II DAC Study for R/R and Elderly Acute AML and MDS
Phase 2 Completed
92 enrolled
Study of Arsenic Trioxide in Small Cell Lung Cancer
Phase 2 Completed
20 enrolled 8 charts
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Phase 1/2 Completed
60 enrolled 7 charts
Arsenic Trioxide in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Previous Hormone Therapy
Phase 2 Completed
37 enrolled
ATO
Phase 1/2 Completed
5 enrolled 9 charts
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Phase 2 Completed
50 enrolled 7 charts
Arsenic Trioxide in Treating Patients With Metastatic Liver Cancer That Cannot Be Removed by Surgery
Phase 2 Completed
25 enrolled
Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
Phase 1/2 Completed
22 enrolled
Arsenic Trioxide, Fluorouracil, and Leucovorin in Treating Patients With Stage IV Colorectal Cancer That Has Relapsed or Not Responded to Treatment
Phase 1 Completed
13 enrolled
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
Phase 2 Completed
22 enrolled 6 charts
Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma
Phase 2 Completed
12 enrolled
Arsenic Trioxide in Treating Young Patients With Refractory Leukemia or Lymphoma
Phase 1 Completed
Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO)
Phase 4 Completed
60 enrolled
Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia
Phase 1 Completed
61 enrolled
Arsenic Trioxide in Treating Patients With Pancreatic Cancer That Has Not Responded to Gemcitabine
Phase 2 Completed
13 enrolled
Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase 2/3 Completed
2,000 enrolled
Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer
Phase 1 Completed
Arsenic Trioxide in Treating Patients With Advanced Solid Tumors
Phase 1 Completed
Arsenic Trioxide in Treating Men With Germ Cell Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Stage IVB or Recurrent Cervical Cancer
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Relapsed or Refractory Non- Hodgkin's Lymphoma
Phase 2 Completed
Arsenic Trioxide in Treating Patients With Metastatic Kidney Cancer
Phase 2 Completed
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Phase 3 Completed
420 enrolled
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
Phase 1/2 Completed
Arsenic Trioxide in Treating Patients With Urothelial Cancer
Phase 2 Completed
35 enrolled
Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Phase 1 Completed
13 enrolled
Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Phase 1 Completed
5 enrolled
Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Phase 1/2 Completed
13 enrolled
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
Phase 1 Completed
30 enrolled
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Phase 1/2 Completed
48 enrolled 3 charts
Arsenic Trioxide in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
30 enrolled
Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia
Phase 2 Completed
35 enrolled
Arsenic Trioxide in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
11 enrolled
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Phase 1/2 Completed
16 enrolled
Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes
Phase 1/2 Completed
32 enrolled
A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec
Phase 2 Completed
6 enrolled
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2 Completed
41 enrolled
Arsenic Trioxide and Radiation Therapy in Treating Young Patients With Newly Diagnosed Gliomas
Phase 1 Completed
36 enrolled
Radiation Therapy, Arsenic Trioxide, and Temozolomide in Treating Patients With Newly Diagnosed High-Grade Glioma
Phase 1 Completed
18 enrolled
Phase I Trial of Arsenic Trioxide and Stereotactic Radiotherapy for Recurrent Malignant Glioma
Phase 1 Completed
12 enrolled
Treatment of Non Promyelocytic Acute Myeloid Leukaemia on Elderly Patients by Low Dose Cytosar Plus Arsenic Trioxide
Phase 2 Completed
10 enrolled
Arsenic Trioxide and Thalidomide in the Treatment of Refractory Multiple Myeloma
Phase 2 Completed
40 enrolled